单位(元)国泰中证生物医药ETF(512290)利润表 |
报告期 |
2024/6/30 |
2023/12/31 |
2023/6/30 |
2022/12/31 |
收入 |
-1,187,681,200 |
-371,376,039 |
-577,452,510 |
-1,019,724,226 |
利息收入 |
958,592 |
5,221,428 |
2,977,676 |
3,651,565 |
其中:存款利息收入 |
44,763 |
127,227 |
68,359 |
154,919 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益 |
-304,876,036 |
-478,392,068 |
-115,535,343 |
-851,006,773 |
其中:股票投资收益 |
-339,719,342 |
-552,669,023 |
-170,492,509 |
-880,076,806 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
- |
- |
- |
648,441 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
34,843,306 |
74,276,955 |
54,957,166 |
28,421,592 |
公允价值变动收益 |
-883,944,409 |
96,062,042 |
-468,387,271 |
-180,291,788 |
汇兑收益 |
- |
- |
- |
- |
其他收入 |
180,653 |
5,732,559 |
3,492,427 |
7,922,770 |
费用 |
12,636,442 |
33,129,061 |
16,279,471 |
23,984,818 |
管理人报酬 |
9,926,278 |
26,078,685 |
12,809,596 |
18,828,026 |
托管费 |
1,985,256 |
5,215,737 |
2,561,919 |
3,765,605 |
销售服务费 |
- |
- |
- |
- |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
721,619 |
1,816,299 |
897,483 |
1,378,597 |
利润总额 |
-1,200,317,642 |
-404,505,100 |
-593,731,981 |
-1,043,709,045 |
减:所得税费用 |
- |
- |
- |
- |
净利润 |
-1,200,317,642 |
-404,505,100 |
-593,731,981 |
-1,043,709,045 |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。